C. Hill

发表

A novel conformationally restricted protein kinase C inhibitor, Ro 31‐8425, inhibits human neutrophil superoxide generation by soluble, particulate and post‐receptor stimuli

P. Davis, M. Dale, B. Twomey, 1991, FEBS letters.

Oxidative cyclisations with palladium acetate. A short synthesis of staurosporine aglycone.

C. Hill, W. Harris, E. Keech, 1993 .

K252a is a potent and selective inhibitor of phosphorylase kinase.

P. Davis, S. Wilkinson, G. Lawton, 1990, Biochemical and biophysical research communications.

Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity.

E. J. Lewis, J. Bishop, P. Davis, 1991, Drugs under experimental and clinical research.

The design and biological properties of potent and selective inhibitors of protein kinase C.

E. J. Lewis, J. Bishop, P. Davis, 1992, Biochemical Society transactions.

Inhibition of bovine nasal cartilage degradation by selective matrix metalloproteinase inhibitors.

N. Borkakoti, P. Eyers, T. Hallam, 1997, The Biochemical journal.

Collagenase and Family

N. Borkakoti, F. Winkler, A. D'arcy, 1998 .

Targets for Drug Design

N. Borkakoti, F. Winkler, E. J. Lewis, 1998 .

A Dieckmann/ring expansion approach to tetrahydropyrido- and tetrahydroazepino-[1,2-a]indoles

D. Vesey, P. Davis, C. Hill, 1991 .

Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain.

Janet L. Smith, D. Vesey, P. Davis, 1994 .

A convenient synthesis of bisindolylmaleimides

P. Crackett, C. Hill, W. Harris, 1993 .

Synthesis and antiviral activity of metabolites of rimantadine.

R. Belshe, J. A. Martin, P. Manchand, 1990, Journal of medicinal chemistry.

Potent selective inhibitors of protein kinase C

P. Davis, S. Wilkinson, G. Lawton, 1989, FEBS letters.

Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction.

D. Vesey, P. Davis, P D Davis, 1993, Journal of medicinal chemistry.

Inhibitors of protein kinase C. 2. Substituted bisindolylmaleimides with improved potency and selectivity.

P. Davis, P D Davis, C H Hill, 1992, Journal of medicinal chemistry.

Therapeutic potential of protein kinase C inhibitors

David Bradshaw, Sandra E. Wilkinson, S. Wilkinson, 2005, Agents and Actions.

The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells

L. Drew, M. Rumsby, J. Merritt, 1999, Cancer Chemotherapy and Pharmacology.

Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides.

P. Davis, P D Davis, C H Hill, 1992, Journal of medicinal chemistry.

Structure-based design of peptidomimetic antagonists of p56lck SH2 domain

I. E. Smith, N. Borkakoti, D. Banner, 2002 .

The design of inhibitors of protein kinase C; the solution conformation of staurosporine

P. Davis, I. Whitcombe, P. D. Davis, 1991 .

Oral, anti-inflammatory activity of a potent, selective, protein kinase C inhibitor

P. Davis, S. Wilkinson, G. Lawton, 1992, Agents and Actions.

(E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.

J. Kneer, D. Walter, R. Devos, 2002, The Journal of pharmacology and experimental therapeutics.